
    <html>
    <head>
    <meta charset="UTF-8">
    <title>Research Report</title>
    <style>
    body,div,ul,li,p,h1,h2,h3,h4 { font-family: 'Segoe UI', 'Roboto', sans-serif; }
    .report-box { background: #f7fafd; border-radius: 16px; border: 1px solid #cde3f7; padding: 32px 24px; margin-bottom:24px; }
    h1 { color: #2261a8; }
    h2, h3 { color: #2674c2; margin-top: 1.6em;}
    h4 { color: #195280; margin-bottom: 0.5em;}
    ul { padding-left: 1.2em; }
    li { margin-bottom: 0.5em;}
    table { border-collapse: collapse; margin: 12px 0;}
    table, th, td { border: 1px solid #9ec6e7; }
    th, td { padding: 8px 12px; }
    .section { margin-bottom: 2em; }
    </style>
    </head>
    <body>
    <div class='report-box'>
<h1>Avendus Overview on India Healthcare Services</h1>
<p><b>Published Date:</b> 2025-06-01</p>
<p><b>Source:</b> Avendus</p>
<h3>Sector</h3>
<p>Healthcare - Single Specialty Hospitals in India</p>
<h3>Period Covered</h3>
<p>June 2025</p>
<h3>Analysts</h3>
<ul><li>Anshul Gupta</li><li>Abhinav Jha</li><li>Prit Shah</li><li>Ajit Prabhakar</li><li>Nisarg Gandhi</li><li>Ayushman Mazumder</li></ul>
<h3>Executive Summary</h3>
<p>Single specialty hospitals in India grew from INR 52K crs (USD 6.3bn) in 2019 to INR 126K crs (USD 15bn) in 2024, 30% share of private healthcare market with 19% CAGR. Expected to reach INR 264K crs (USD 31bn) by 2028, 40% market share, CAGR 20%. Organized single specialty hospitals growing at 24% CAGR (2024-28). Leading specialties include IVF, Eyecare, Mother &amp; Child, Oncology, Dialysis, and emerging ones like Dental, Urology, Skin &amp; Hair Care. Major PE investments of over INR 11 bn since 2015, market cap of listed single specialty hospitals projected to reach INR 150K crs (USD 18 bn) by FY30.</p>
<h3>Overall Sentiment</h3>
<p>Positive</p>
<h3>Overall Sentiment Triggers</h3>
<ul><li>Large TAM expansion with expected 20% CAGR in single specialty segment to 2028.</li><li>Strong private equity investments (e.g., INR 11 bn in hospitals since 2015) and increasing public listings.</li><li>Attractive unit economics with 20%+ EBITDA margins and high ROCE in mature centers.</li><li>Scalable business models driven by brand building and M&amp;A roll-up strategies across specialties.</li><li>Growing organized market shares in IVF (~55%), Eyecare (~65%), and Dialysis (~21%).</li></ul>
<h3>Sector Highlights</h3>
<p>Strong growth drivers include aging population, rise in lifestyle diseases, affordability, insurance expansion, and technology adoption. Single specialty hospitals optimized for scalable, capital-efficient models, with higher brand equity and patient focus. Large opportunities remain in Tier 2+ cities. Increasing private equity interest accelerates consolidation and capital inflows, especially in IVF, Oncology, and Eyecare.</p>
<h3>Industry Metrics Tables</h3>
<h4>[Table ID 1] Indian Healthcare Market Size and Growth</h4>
<div><p>Overall and segment-wise market breakdown in INR crores and USD billion with growth projections 2019-2028P.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Segment</th>
      <th>2019 (INR cr)</th>
      <th>2019 (USD bn)</th>
      <th>2024 (INR cr)</th>
      <th>2024 (USD bn)</th>
      <th>2028P (INR cr)</th>
      <th>2028P (USD bn)</th>
      <th>CAGR</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Total Healthcare</td>
      <td>1070000</td>
      <td>130</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td>10%</td>
    </tr>
    <tr>
      <td>Hospital Market</td>
      <td>630000</td>
      <td>76</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td>12%</td>
    </tr>
    <tr>
      <td>Private &amp; Trust Hospitals Share</td>
      <td>67%</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
    <tr>
      <td>Single Specialty Hospitals (Private + Trust)</td>
      <td>52000</td>
      <td>6.3</td>
      <td>126000</td>
      <td>15</td>
      <td>264000</td>
      <td>31</td>
      <td>19-20%</td>
    </tr>
    <tr>
      <td>Organized Single Specialty Hospitals</td>
      <td>12000</td>
      <td>1.5</td>
      <td>32000</td>
      <td>4</td>
      <td>76000</td>
      <td>9</td>
      <td>24%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 2] Single Specialty Hospital Market Shares by Specialty in 2024 and 2028P</h4>
<div><p>Market size split by specialty segments in INR crores with market shares in organized single specialty hospitals.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Specialty</th>
      <th>2024 Organized Market (INR cr)</th>
      <th>% Share</th>
      <th>2028P Organized Market (INR cr)</th>
      <th>% Share.1</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Eyecare</td>
      <td>27000.0</td>
      <td>36%</td>
      <td>50000-60000</td>
      <td>27-30%</td>
    </tr>
    <tr>
      <td>Mother &amp; Child</td>
      <td>19000.0</td>
      <td>25%</td>
      <td>38000-39000</td>
      <td>21-23%</td>
    </tr>
    <tr>
      <td>IVF</td>
      <td>13000.0</td>
      <td>17%</td>
      <td>32000-38000</td>
      <td>17-21%</td>
    </tr>
    <tr>
      <td>Oncology</td>
      <td>12000.0</td>
      <td>16%</td>
      <td>26000-27000</td>
      <td>15-16%</td>
    </tr>
    <tr>
      <td>Dialysis</td>
      <td>5000.0</td>
      <td>7%</td>
      <td>11000</td>
      <td>6%</td>
    </tr>
    <tr>
      <td>Urology / Nephrology</td>
      <td>7000.0</td>
      <td>9%</td>
      <td>17000-18000</td>
      <td>9-10%</td>
    </tr>
    <tr>
      <td>Dental Care</td>
      <td>2000.0</td>
      <td>3%</td>
      <td>6500-7000</td>
      <td>4%</td>
    </tr>
    <tr>
      <td>Skin &amp; Hair Care</td>
      <td>NaN</td>
      <td>5%</td>
      <td>17000-18000</td>
      <td>10%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>4%</td>
      <td></td>
      <td></td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 3] Competitive Landscape: IVF Chains Revenue and Market Share FY24</h4>
<div><p>Top IVF chains by FY24 revenue INR crs and organized market share percentage.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Indira IVF</td>
      <td>1476.0</td>
      <td>35%</td>
    </tr>
    <tr>
      <td>Nova IVF</td>
      <td>1000.0</td>
      <td>30%</td>
    </tr>
    <tr>
      <td>Oasis</td>
      <td>370.0</td>
      <td>12%</td>
    </tr>
    <tr>
      <td>Birla IVF</td>
      <td>200.0</td>
      <td>5%</td>
    </tr>
    <tr>
      <td>Iswarya</td>
      <td>183.0</td>
      <td>5%</td>
    </tr>
    <tr>
      <td>Cloudnine</td>
      <td>135.0</td>
      <td>4%</td>
    </tr>
    <tr>
      <td>Ferty9</td>
      <td>132.0</td>
      <td>3%</td>
    </tr>
    <tr>
      <td>Sudha</td>
      <td>104.0</td>
      <td>3%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>8%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 4] Competitive Landscape: Eyecare Chains Revenue and Market Share FY24</h4>
<div><p>Major eyecare chains revenue and market share.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dr Agarwal</td>
      <td>1332.0</td>
      <td>20%</td>
    </tr>
    <tr>
      <td>ASG Eye Hospitals</td>
      <td>792.0</td>
      <td>43%</td>
    </tr>
    <tr>
      <td>Center for Sight</td>
      <td>472.0</td>
      <td>12%</td>
    </tr>
    <tr>
      <td>Disha Eye Hospitals</td>
      <td>362.0</td>
      <td>7%</td>
    </tr>
    <tr>
      <td>Maxivision</td>
      <td>316.0</td>
      <td>5%</td>
    </tr>
    <tr>
      <td>Eye Foundation</td>
      <td>NaN</td>
      <td>2%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>16%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 5] Competitive Landscape: Mother &amp; Child Chains Revenue and Market Share FY24</h4>
<div><p>Top mother &amp; child care chains revenue and market share.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cloudnine</td>
      <td>1297.0</td>
      <td>26%</td>
    </tr>
    <tr>
      <td>Motherhood</td>
      <td>1188.0</td>
      <td>29%</td>
    </tr>
    <tr>
      <td>Ankura</td>
      <td>700.0</td>
      <td>14%</td>
    </tr>
    <tr>
      <td>Fernandez</td>
      <td>374.0</td>
      <td>23%</td>
    </tr>
    <tr>
      <td>Surya Hospitals</td>
      <td>280.0</td>
      <td>13%</td>
    </tr>
    <tr>
      <td>Apollo Cradle</td>
      <td>230.0</td>
      <td>7%</td>
    </tr>
    <tr>
      <td>Sabine</td>
      <td>200.0</td>
      <td>6%</td>
    </tr>
    <tr>
      <td>Rainbow Children's Hospitals</td>
      <td>156.0</td>
      <td>4%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>1%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 6] Competitive Landscape: Dialysis Chains Revenue and Market Share FY24</h4>
<div><p>Top dialysis players revenue and market share.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NephroPlus</td>
      <td>566.0</td>
      <td>43%</td>
    </tr>
    <tr>
      <td>Apollo Dialysis</td>
      <td>176.0</td>
      <td>6%</td>
    </tr>
    <tr>
      <td>Apex Kidney Care</td>
      <td>128.0</td>
      <td>18%</td>
    </tr>
    <tr>
      <td>DCDC Kidney Care</td>
      <td>118.0</td>
      <td>12%</td>
    </tr>
    <tr>
      <td>Eskag Sanjeevani</td>
      <td>96.0</td>
      <td>12%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>10%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 7] Competitive Landscape: Oncology Chains Revenue and Market Share FY24</h4>
<div><p>Leading comprehensive cancer care (CCC) chains revenue and market share.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>HCG</td>
      <td>1845.0</td>
      <td>48%</td>
    </tr>
    <tr>
      <td>Omega</td>
      <td>720.0</td>
      <td>11%</td>
    </tr>
    <tr>
      <td>AOI</td>
      <td>380.0</td>
      <td>19%</td>
    </tr>
    <tr>
      <td>ClearMedi</td>
      <td>171.0</td>
      <td>10%</td>
    </tr>
    <tr>
      <td>MOC</td>
      <td>153.0</td>
      <td>4%</td>
    </tr>
    <tr>
      <td>Renova</td>
      <td>100.0</td>
      <td>4%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>4%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 8] Competitive Landscape: Dental Care Chains Revenue and Market Share FY24</h4>
<div><p>Revenue and market share among dental chains.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Clove Dental</td>
      <td>305.0</td>
      <td>47%</td>
    </tr>
    <tr>
      <td>Dentzz</td>
      <td>75.0</td>
      <td>18%</td>
    </tr>
    <tr>
      <td>Partha Dental</td>
      <td>55.0</td>
      <td>11%</td>
    </tr>
    <tr>
      <td>Sabka Dentist</td>
      <td>54.0</td>
      <td>8%</td>
    </tr>
    <tr>
      <td>Apollo Dental</td>
      <td>53.0</td>
      <td>8%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>8%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 9] Competitive Landscape: Urology Chains Revenue and Market Share FY24</h4>
<div><p>Key urology players with revenue and organized market share.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>RG Stone</td>
      <td>221.0</td>
      <td>33%</td>
    </tr>
    <tr>
      <td>AINU</td>
      <td>180.0</td>
      <td>16%</td>
    </tr>
    <tr>
      <td>NU Hospitals</td>
      <td>160.0</td>
      <td>27%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>24%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 10] Competitive Landscape: Skin &amp; Hair Care Chains Revenue and Market Share FY24</h4>
<div><p>Leading skin &amp; hair care chains revenue and share.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>FY24 Revenue (INR cr)</th>
      <th>Market Share %</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Kaya</td>
      <td>964.0</td>
      <td>25%</td>
    </tr>
    <tr>
      <td>VCare</td>
      <td>404.0</td>
      <td>38%</td>
    </tr>
    <tr>
      <td>Bodycraft</td>
      <td>258.0</td>
      <td>10%</td>
    </tr>
    <tr>
      <td>Oliva</td>
      <td>100.0</td>
      <td>5%</td>
    </tr>
    <tr>
      <td>Kolors</td>
      <td>97.0</td>
      <td>5%</td>
    </tr>
    <tr>
      <td>Eugenix</td>
      <td>70.0</td>
      <td>9%</td>
    </tr>
    <tr>
      <td>VLCC</td>
      <td>60.0</td>
      <td>4%</td>
    </tr>
    <tr>
      <td>Others</td>
      <td>NaN</td>
      <td>9%</td>
    </tr>
  </tbody>
</table></div>
<h3>Charts And Figures</h3>
<ul>
<li><b>[Chart ID 1] India Private Healthcare Market Growth 2019-2028P</b>: Shows growth of India healthcare market and rising share of private and trust hospitals from 67% of INR 630K crs in hospital market.</li>
<li><b>[Chart ID 2] Single Specialty Hospitals Market Share and Growth</b>: Single specialty hospitals share grew from 20% in 2019 to 30% in 2024, projected 40% in 2028 with organized single specialty growing at 24% CAGR.</li>
<li><b>[Chart ID 3] Market Size and Growth of Single Specialty Segments</b>: TAM for IVF, Eyecare, Dialysis, Oncology etc., with growth projections for 2024 to 2028, CAGR range typically 12%-17%.</li>
<li><b>[Chart ID 4] Private Equity Investments in Single Specialty Hospitals 2015-2025</b>: Shows increasing PE deal sizes and differentiation between single specialty and multi-specialty investments, with single specialty rising to 36% of total hospital investments.</li>
<li><b>[Chart ID 5] IVF Market Size and Penetration Globally</b>: India has high reproductive age population, lowest IVF penetration (cycles per 1000 women), low IVF costs but growing market opportunity to 2028.</li>
<li><b>[Chart ID 6] Eyecare Market Epidemiology and Market Size</b>: India has highest number of visual impairment and cataracts prevalence driving eyecare market to INR 50-60K crs by 2028.</li>
<li><b>[Chart ID 7] Oncology Market and Treatment Gap</b>: India 2nd highest cancer incidence with large demand-supply gap in oncologists, market growing to INR 42-44K crs by 2028 with low early detection rates.</li>
</ul>
<h3>Macro Trends</h3>
<p>India&#x27;s healthcare spending is growing at 10% CAGR with 67% market share held by private and trust hospitals. Increasing prevalence of chronic diseases and lifestyle conditions such as diabetes and obesity. Rising median age and expansion of insurance coverage. Medical tourism reputation growth. Government initiatives improving affordability and access. Urbanization and rising disposable incomes support healthcare consumption.</p>
<h3>Headwinds Tailwinds</h3>
<b>Headwinds:</b>
<ul><li>Pricing pressures and caps especially in high-volume procedures like cataract surgeries.</li><li>Regulatory constraints and supply restrictions (e.g., for gamete donors in IVF).</li><li>Limited penetration and reimbursement for novel therapies (e.g., CAR-T cell therapy) may limit adoption.</li><li>Localized business models and high doctor attrition in some specialties (e.g., dental care).</li><li>Rural and Tier 2+ expansion challenges due to infrastructure and patient proximity preferences.</li></ul>
<b>Tailwinds:</b>
<ul><li>Increasing incidence of lifestyle diseases and aging population boosting demand.</li><li>Technology advancements improving outcomes and scalability.</li><li>Growing private equity and public market funding enabling consolidation and infrastructure expansion.</li><li>Improved health awareness and insurance penetration enhancing affordability.</li><li>High clinical focus and favorable unit economics allowing rapid scale of single specialty chains.</li></ul>
<h3>Key Statistics</h3>
<ul><li>Single specialty hospitals grew at 19% CAGR 2019-2024, expected 20% CAGR to 2028.</li><li>Organized single specialty hospitals growing at 24% CAGR (2024-28).</li><li>IVF market expected to reach INR 12K-14K crs by 2028 with ~550K IVF cycles annually.</li><li>Eyecare market to reach INR 50K-60K crs by 2028 with cataract cases at 13.3 crs.</li><li>Mother &amp; Child care market projected INR 41K+ crs by 2028 with pediatrics at INR ~170K crs.</li><li>Dialysis market to grow at ~16% CAGR to INR ~11K crs by 2028.</li><li>Oncology market expected to reach INR 42Kâ€“44K crs by 2028 at 13%-14% CAGR.</li><li>Dental care market to reach INR 68K crs and orthodontics INR 14K crs by 2028.</li><li>Urology market estimated to reach INR ~47K crs by 2028 at 14% CAGR.</li><li>Skin &amp; Hair care market projected INR ~41K crs by 2028 at ~17% CAGR.</li></ul>
<h3>Company Summaries</h3>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Indira IVF <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Pan India IVF chain with FY24 revenue INR 1476 cr, 35% organized market share, 32% revenue CAGR FY21-24, 34% operating EBITDA.<br>
<b>Rationale:</b> Leader in India IVF with national footprint, strong PE backing and high growth trajectory.<br>
<b>Triggers:</b> <ul><li>High market share</li><li>Strong revenue and EBITDA growth</li><li>PE interest</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 3 and 5</pre>
<b>Outlook/Guidance:</b> Positive market growth with driven by demographic and regulatory tailwinds.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 3, 32<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Dr Agarwal&#x27;s Eye Hospitals <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> India&#x27;s largest ophthalmic chain with FY24 revenue INR 1332 cr, 20% market share, 41% revenue CAGR FY21-24, 27% operating EBITDA.<br>
<b>Rationale:</b> Strong brand with pan-India presence, technology adoption and consistent profitability.<br>
<b>Triggers:</b> <ul><li>Leading eyecare revenue</li><li>Strong margin profile</li><li>Robust funding</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 4 and 46</pre>
<b>Outlook/Guidance:</b> Expected to benefit from aging and lifestyle disease growth.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 4, 46<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Cloudnine <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Pan-India Mother &amp; Child care chain with FY24 revenue INR 1297 cr, 26% organized market share, 26% CAGR FY21-24, 33% operating EBITDA.<br>
<b>Rationale:</b> Leader in Mother &amp; Child care segment with geographic reach and balanced maternity and pediatrics services.<br>
<b>Triggers:</b> <ul><li>Large market share</li><li>Strong revenue growth</li><li>PE investor backing</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 5 and 57</pre>
<b>Outlook/Guidance:</b> Growing institutional deliveries and rising urban demand.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 5, 57<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>NephroPlus <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Largest dialysis chain in India, FY24 revenue INR 566 cr, 43% organized market share, 26% CAGR FY21-24, ~20% operating EBITDA.<br>
<b>Rationale:</b> Market leader with extensive network and steady growth.<br>
<b>Triggers:</b> <ul><li>Highest dialysis revenue</li><li>Significant capacity expansion</li><li>High EBITDA margins</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 6 and 70</pre>
<b>Outlook/Guidance:</b> Volume growth due to rising CKD, insurance and govt. initiatives.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 6, 70<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>HCG (Healthcare Global) <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Leading Comprehensive Cancer Care (CCC) chain, FY24 revenue INR 1845 cr, 48% CCC market share, 23% CAGR FY21-24, ~20% operating EBITDA.<br>
<b>Rationale:</b> Pioneer in CCC with diversified treatment modalities and pan-India presence.<br>
<b>Triggers:</b> <ul><li>Largest oncology CCC revenue</li><li>Strong growth and profitability</li><li>Robust PE backing</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 7 and 81</pre>
<b>Outlook/Guidance:</b> Favorable demographics and increasing cancer incidence.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 7, 81<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Clove Dental <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Largest organized dental chain with FY24 revenue INR 305 cr, 47% market share of dental chains, 25% EBITDA margin.<br>
<b>Rationale:</b> Market leader with scalable model and unique in-house product portfolio including aligners.<br>
<b>Triggers:</b> <ul><li>Leading revenue share</li><li>High margin profile</li><li>Strong PE interest</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 8 and 94</pre>
<b>Outlook/Guidance:</b> Growth driven by rising oral health awareness and technology adoption.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 8, 94<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>RG Stone Urology <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Key urology player with FY24 revenue INR 221 cr, 33% market share, 28% CAGR FY21-24, 15% EBITDA.<br>
<b>Rationale:</b> One of the largest players in underserved urology market with asset light model.<br>
<b>Triggers:</b> <ul><li>High market share</li><li>Strong revenue CAGR</li><li>Growing investor interest</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 9 and 105</pre>
<b>Outlook/Guidance:</b> Increasing volume demand driven by aging and lifestyle diseases.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 9, 105<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Kaya Skin Care <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Leading skin &amp; hair care chain, FY24 revenue INR 964 cr, 25% organized market share, 22% CAGR FY21-24, 14% EBITDA margin.<br>
<b>Rationale:</b> Pan India presence with wide service offerings and scaling operations.<br>
<b>Triggers:</b> <ul><li>High revenue</li><li>Geographic expansion</li><li>Moderate margins</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Tables 10 and 114</pre>
<b>Outlook/Guidance:</b> Strong growth expected from rising lifestyle issues and discretionary spend.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 10, 114<br>
</div>
<h3>Conclusion</h3>
<p>The Indian single specialty healthcare sector is experiencing robust growth fueled by demographic shifts, technology adoption, and strong capital investment. Established specialties like IVF, Eyecare, Mother &amp; Child, Dialysis, and Oncology have scaled significantly, attracting substantial private equity and public market interest. Emerging specialties such as Dental, Urology, and Skin &amp; Hair Care also present compelling growth prospects. Consolidation, technological innovation, and expansion beyond metro areas are expected to accelerate, creating attractive opportunities for investors and operators alike. Single specialty models demonstrate superior unit economics, scalability, and patient outcomes compared to multi-specialty setups, reinforcing positive sector outlook.</p>
<h3>Data Sources</h3>
<p>Avendus proprietary research, Company filings, Public market reports, Industry reports, WHO, UN, Crisil, MMR Journal, National Library of Medicine, Global Health Data Exchange, Primary research, Investor presentations, News articles.</p>
<h3>Sector Specific</h3>
<p>Single Specialty Healthcare in India: Detailed TAM estimates, market segmentation, and unit economics per specialty. Comprehensive analysis of maturity, growth rates, investment trends, and operational models for IVF, Eyecare, Mother &amp; Child, Dialysis, Oncology, Dental, Urology, Skin &amp; Hair Care. Regulatory landscape impacts (e.g., ART Act 2021). Supply-demand gaps, technology adoption rates, and healthcare infrastructure variations across metro and non-metro regions. PE investment flows and public market capitalization projections. Business model archetypes (hub &amp; spoke, large format, roll-up M&amp;A). Patient acquisition channels and competitive positioning within and across specialties.</p>
<h3>Other Remarks</h3>
<p>The report highlights the strong potential of single specialty chains to gain market share from multi-specialty hospitals by providing focused, efficient, and patient-centric care. The sector shows increasing professionalization, brand building, and sophistication in care delivery. Challenges include pricing pressures, regulatory compliance, rural penetration, and technology obsolescence costs. Continuous innovation and expansion into Tier 2+ cities will be critical drivers for sustained growth. Investor interest is likely to grow alongside rising healthcare demand and sector consolidation.</p>
</div>
    </body>
    </html>
    